论文部分内容阅读
1993年3月~1995年12月,20例无手术切除指征的肝癌患者接受rIL-2/LAK过继免疫治疗,其中6例(30%)获部分缓解。16例肝癌患者于治疗前后行免疫功能测定,结果显示:1)原发性肝癌病人外周T细胞亚群及NK活性是明显抑制状态(P<0.001);2)患者经过过继免疫治疗后,T细胞工群及NK细胞活性明显改善。上述结果表明原发性肝癌病人是明显免疫抑制状态,采用rIL-2/LAK区域过继免疫治疗有效。
From March 1993 to December 1995, 20 patients with unresectable hepatocellular carcinoma received rIL-2/LAK adoptive immunotherapy, and 6 of them (30%) received partial remission. Immune function was measured in 16 patients with liver cancer before and after treatment. The results showed that: 1) Peripheral T-cell subsets and NK activity were significantly inhibited in patients with primary liver cancer (P<0.001); 2) Patients after adoptive immunotherapy The T cell population and NK cell activity were significantly improved. The above results indicate that the primary liver cancer patients are significantly immunosuppressed, and adoptive immunotherapy with rIL-2/LAK is effective.